We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current NOV market cap is 361.97B. The company's latest EPS is DKK 18.6127 and P/E is 4.52.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Revenue | 122.02B | 126.95B | 140.8B | 176.95B | 232.26B |
| Operating Income | 52.35B | 54.28B | 58.62B | 74.62B | 102.66B |
| Net Income | 38.95B | 42.14B | 47.76B | 55.53B | 83.68B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Assets | 125.61B | 144.92B | 194.51B | 241.26B | 314.49B |
| Total Liabilities | 68.02B | 81.6B | 123.76B | 157.77B | 207.93B |
| Total Equity | 57.59B | 63.33B | 70.75B | 83.49B | 106.56B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Operating | 46.78B | 51.95B | 55B | 78.89B | 108.91B |
| Investing | -11.51B | -22.44B | -31.61B | -24.92B | -43.89B |
| Financing | -35.48B | -32.24B | -25.49B | -51.8B | -63.16B |
| Market Cap | 361.97B |
| Price to Earnings Ratio | 4.52 |
| Price to Sales Ratio | 1.63 |
| Price to Cash Ratio | 26.28 |
| Price to Book Ratio | 3.55 |
| Dividend Yield | 91.75% |
| Shares Outstanding | 4.5B |
| Average Volume (1 week) | 144.63k |
| Average Volume (1 Month) | 182.27k |
| 52 Week Change | -23.85% |
| 52 Week High | 139.88 |
| 52 Week Low | 9.6779 |
| Spread (Intraday) | 0.03 (0.04%) |
| Company Name | Novo Nordisk |
| Address |
novo alle bagsvaerd DK-2880 |
| Website | https://www.novonordisk.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
